230 related articles for article (PubMed ID: 30846478)
21. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
Ng YZ; Pourreyron C; Salas-Alanis JC; Dayal JH; Cepeda-Valdes R; Yan W; Wright S; Chen M; Fine JD; Hogg FJ; McGrath JA; Murrell DF; Leigh IM; Lane EB; South AP
Cancer Res; 2012 Jul; 72(14):3522-34. PubMed ID: 22564523
[TBL] [Abstract][Full Text] [Related]
22. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl.
Shivaswamy KN; Sumathy TK; Shyamprasad AL; Ranganathan C
Int J Dermatol; 2009 Jul; 48(7):731-3. PubMed ID: 19570079
[TBL] [Abstract][Full Text] [Related]
23. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.
Welponer T; Weber DD; Trattner L; Tockner B; Aminzadeh-Gohari S; Leb-Reichl V; Kaufmann A; Zauner R; Wimmer M; Wally V; Felder TK; Strunk D; Koller U; Bauer JW; Kofler B; Guttmann-Gruber C; Piñon Hofbauer J
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):112-123. PubMed ID: 37669776
[TBL] [Abstract][Full Text] [Related]
24. TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.
Knaup J; Gruber C; Krammer B; Ziegler V; Bauer J; Verwanger T
Anal Cell Pathol (Amst); 2011; 34(6):339-53. PubMed ID: 22002724
[TBL] [Abstract][Full Text] [Related]
25. Management of squamous cell carcinoma in a patient with recessive-type epidermolysis bullosa dystrophica.
Yamada M; Hatta N; Sogo K; Komura K; Hamaguchi Y; Takehara K
Dermatol Surg; 2004 Nov; 30(11):1424-9. PubMed ID: 15522026
[TBL] [Abstract][Full Text] [Related]
26. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
[TBL] [Abstract][Full Text] [Related]
27. MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa.
Hata H; Abe R; Suto A; Homma E; Fujita Y; Aoyagi S; Shimizu H
Br J Dermatol; 2015 Mar; 172(3):769-73. PubMed ID: 25066310
[TBL] [Abstract][Full Text] [Related]
28. Evaluating a Targeted Cancer Therapy Approach Mediated by RNA
Woess K; Sun Y; Morio H; Stierschneider A; Kaufmann A; Hainzl S; Trattner L; Kocher T; Tockner B; Leb-Reichl V; Steiner M; Brachtl G; South AP; Bauer JW; Reichelt J; Furihata T; Wally V; Koller U; Piñón Hofbauer J; Guttmann-Gruber C
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008999
[TBL] [Abstract][Full Text] [Related]
29. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa. A report of 4 patients with 17 primary cutaneous malignancies.
Newman C; Wagner RF; Tyring SK; Spigel GT
J Dermatol Surg Oncol; 1992 Apr; 18(4):301-5. PubMed ID: 1560154
[TBL] [Abstract][Full Text] [Related]
30. Spliceosome-mediated RNA trans-splicing facilitates targeted delivery of suicide genes to cancer cells.
Gruber C; Gratz IK; Murauer EM; Mayr E; Koller U; Bruckner-Tuderman L; Meneguzzi G; Hintner H; Bauer JW
Mol Cancer Ther; 2011 Feb; 10(2):233-41. PubMed ID: 21209069
[TBL] [Abstract][Full Text] [Related]
31. Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa-Hallopeau-Siemens: a report of four cases.
Dammak A; Zribi J; Boudaya S; Mseddi M; Meziou TJ; Masmoudi A; Ellouze Z; Keskes H; Turki H
Int J Dermatol; 2009 Jun; 48(6):588-91. PubMed ID: 19538366
[TBL] [Abstract][Full Text] [Related]
32. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases.
Hwang A; Kwon A; Miller CH; Reimer-Taschenbrecker A; Paller AS
Orphanet J Rare Dis; 2024 May; 19(1):206. PubMed ID: 38769503
[TBL] [Abstract][Full Text] [Related]
33. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.
Twaroski K; Eide C; Riddle MJ; Xia L; Lees CJ; Chen W; Mathews W; Keene DR; McGrath JA; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1247-1253. PubMed ID: 30924923
[TBL] [Abstract][Full Text] [Related]
34. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis.
Smoller BA; McNutt NS; Carter DM; Gottlieb AB; Hsu A; Krueger J
Arch Dermatol; 1990 Jan; 126(1):78-83. PubMed ID: 1688702
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years' experience of a reference centre in Spain.
Castelo B; Viñal D; Maseda R; Ostios L; Sánchez D; García-Salvatierra B; Escámez MJ; Martínez-Santamaría L; Del Río M; Mora-Rillo M; Vilches Y; Beato MJ; López Gutiérrez JC; Romero N; Santos C; Miranda J; de Lucas R
Clin Transl Oncol; 2019 Nov; 21(11):1573-1577. PubMed ID: 30864020
[TBL] [Abstract][Full Text] [Related]
36. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin.
Fine JD; Johnson LB; Weiner M; Stein A; Suchindran C
J Am Acad Dermatol; 2004 Apr; 50(4):563-71. PubMed ID: 15034505
[TBL] [Abstract][Full Text] [Related]
37. Understanding the pathogenesis of recessive dystrophic epidermolysis bullosa squamous cell carcinoma.
South AP; O'Toole EA
Dermatol Clin; 2010 Jan; 28(1):171-8. PubMed ID: 19945632
[TBL] [Abstract][Full Text] [Related]
38. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
Arbiser JL; Fine JD; Murrell D; Paller A; Connors S; Keough K; Marsh E; Folkman J
Mol Med; 1998 Mar; 4(3):191-5. PubMed ID: 9562977
[TBL] [Abstract][Full Text] [Related]
39. Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma.
Watt SA; Pourreyron C; Purdie K; Hogan C; Cole CL; Foster N; Pratt N; Bourdon JC; Appleyard V; Murray K; Thompson AM; Mao X; Mein C; Bruckner-Tuderman L; Evans A; McGrath JA; Proby CM; Foerster J; Leigh IM; South AP
Oncogene; 2011 Nov; 30(46):4666-77. PubMed ID: 21602893
[TBL] [Abstract][Full Text] [Related]
40. Metastatic squamous cell carcinoma resembling angiosarcoma complicating dystrophic epidermolysis bullosa.
McGrath JA; Schofield OM; Mayou BJ; McKee PH; Eady RA
Dermatologica; 1991; 182(4):235-8. PubMed ID: 1884860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
